Sigumir

Sigumir is a synthetic tetrapeptide (Val-Glu-Pro-Asp) bioregulator from Professor Khavinson's research program, derived from cartilage tissue. It targets articular and intervertebral cartilage — tissues that undergo progressive degeneration with aging, ultimately manifesting as osteoarthritis and degenerative disc disease.

Cartilage is an avascular tissue maintained almost entirely by chondrocytes, which must produce and maintain the extracellular matrix (primarily type II collagen, aggrecan, and hyaluronic acid) throughout life. With aging, chondrocyte anabolic capacity declines (reduced collagen II and proteoglycan synthesis), catabolic enzyme activity increases (MMP-13, ADAMTS-4/5), and the tissue becomes thinner, less hydrated, and more susceptible to mechanical failure.

In the Khavinson bioregulator framework, Sigumir is proposed to interact with DNA promoter regions relevant to cartilage matrix gene expression, upregulating production of structural proteins needed for ECM maintenance. Published research from the Khavinson group includes cell culture studies showing increased DNA synthesis in cartilage cells treated with related peptide bioregulators, and clinical studies in elderly patients showing improved joint function metrics.

Sigumir is frequently included in musculoskeletal anti-aging protocols alongside Cartalax (another cartilage bioregulator, already in the database) and Epithalon. The distinction between Sigumir and Cartalax in the Khavinson system relates to their specific peptide sequences and proposed gene-regulatory profiles, though both target cartilage tissue.